Synapse Open Synapse
Biology

Novartis wagers almost $8B on a Chinese biotech’s RNA drugs

BioPharma Dive ·

In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.

Latest from BioPharma Dive